Investment Strategy

Specialist conviction where clinical need, technology inflection, and compelling business economics converge

We invest globally in diagnostic and therapeutic medical devices that can change the course of care in cardiology, neurology, and surgical oncology.

3.1
Why Medical Devices

Problems we understand. Outcomes we can help engineer

Medical-device innovation draws directly on our strengths in electrical, mechanical, software, and systems engineering. We can examine how a product works, how it fits anatomy and clinical workflow, and how defined milestones can reduce risk.

Device development can offer an observable, iterative path to validation: designs can be tested, measured, refined, and retested. Outcomes are never assured, but clinical performance is often tied to engineering parameters that teams can improve—creating the potential for greater development predictability.

Devices can also provide definitive intervention. In selected conditions, a procedure may correct anatomy, restore function, remove disease, or interrupt a pathological process directly rather than merely manage its symptoms.

From an investment perspective, medical devices can offer more observable development milestones, clearer regulatory pathways in many categories, lower pre-commercial capital requirements than drug development, and multiple strategic-acquisition pathways. These characteristics do not eliminate risk, but they can make risk more visible, stage-gated and manageable.

AI, advanced visualization, robotics, bioelectronics and connected devices are now converging with clinical and commercial maturity, expanding what medical devices can diagnose, treat and restore.

Engineering-led

Measurable, testable, iterative development

De-riskable

Evidence accumulates across defined milestones

Definitive

Potential to diagnose or treat the underlying problem
3.2
Clinical Focus

Three fields where need, technology, and specialist insight converge

0.1

Cardiology

Cardiovascular disease remains one of the world’s largest causes of death and disability, while care continues to move toward catheter-based intervention, structural repair, rhythm management, and continuous physiological insight.
Diagnostics & Monitoring
Interventional / Vascular
Electrophysiology
Structural Heart
Heart Failure / MCS
0.2

Neurology

The brain is medicine’s least understood organ. Better sensing, imaging, navigation, neuromodulation, and minimally invasive intervention can transform conditions for which existing options remain limited or imprecise.
Diagnostics & Monitoring
Neuromodulation
Neurointervention / Neurosurgery
BCI / Neurorehabilitation
Cognitive / Behavioral Technologies
0.3

Surgical Oncology

Cancer surgery is often limited by what can be seen, reached, and removed safely. Intraoperative diagnostics and precision tools can help clinicians localize disease, define margins, navigate anatomy, and treat tumors more completely.
Intraoperative Visualization
Tumor Localization
Margin Assessment
Precision Instrumentation
Robotics / Navigation
Within these domains, we focus on categories where clinical urgency, technology inflection and strategic-buyer interest converge.

Our oncology focus is surgical and interventional. Sloan invests in medical-device technologies rather than drug-development programs.

3.3
Technology Inflections
We are modality-aware but not modality-bound. We focus on cross-cutting technology inflections that materially improve what physicians can detect, understand, navigate, treat or restore.

From better signals to more precise intervention

0.1

Signal Intelligence

Computational interpretation of physiologic, imaging and procedural signals that can reveal clinically useful information earlier or more precisely.
0.2

Advanced Spectral Imaging

Fluorescence, hyperspectral, Raman, photoacoustic and related approaches that extend visualization beyond conventional imaging.
0.3

Physical Biomarkers

Disease signatures derived from motion, pressure, acoustics, spectra, electrophysiology and other physical or physiologic signals.
0.4

Bioelectronic Intervention

Pacing, ablation, stimulation and closed-loop technologies that modulate biological function through precisely delivered energy.
0.5

Precision Access & Robotics

Catheters, navigation, robotic systems and minimally invasive delivery technologies that improve access, precision and procedural consistency.
0.6

Connected Longitudinal Monitoring

Implantables, wearables and remote-monitoring platforms that extend clinical observation beyond episodic encounters.
Sloan invests in medical devices, not drug-development programs. Enabling materials, sensors or molecular technologies may be within scope when they are integral to a medical-device platform.
3.4
Stage, Geography & Strategy

Global access. Concentrated where opportunity is deepest

Expected portfolio geography

0 %
North America
0 %
Europe
0 %
Rest of World

Computational interpretation of physiologic, imaging and procedural signals that can reveal clinically useful information earlier or more precisely.

Core Strategy

$1M–$5M

Typical initial investment

Primarily Series A and Series B, with selective Seed and Series C investments where the company’s risk profile, evidence and opportunity justify an earlier or later entry point.
3.5
Investment Criteria
We look for companies in which clinical importance, credible evidence, differentiated technology, compelling business economics and a realistic path to adoption reinforce one another.

What earns our conviction

0.1

High clinical impact

Addresses an important unmet need and has the potential to materially improve outcomes, safety, access, or cost of care.
0.2

Credible evidence

Supported by credible scientific, preclinical, clinical, or real-world evidence appropriate to the company’s stage.
0.3

Right stage & risk profile

Generally Series A or B, with selective earlier or later investments where principal technical risks are becoming understandable and specialist support can still materially influence the company’s trajectory.
0.4

Technology–need fit

The enabling technology is not merely novel; it is well matched to the clinical problem, workflow, users, and care setting
0.5

Clear path to adoption

A credible regulatory, reimbursement, manufacturing and physician-adoption pathway—with a business model and value proposition that matter to patients, clinicians, providers and payers.
0.6

Defensible advantage

Meaningful intellectual property, proprietary know-how, clinical data, workflow integration, or another durable source of differentiation.
0.7

Exceptional, coachable team

Founders with integrity, urgency, domain insight, and the ability to recruit the broader capabilities required to build a world-class medical-device company.
0.8

Compelling economics & capital-efficient value creation

A business model with attractive economics, achievable financing requirements and identifiable milestones that can reduce risk, expand strategic options and create long-term value.

Strategic relevance from the outset.

We consider how an emerging technology fits the capabilities, portfolio gaps and strategic priorities of established medical-device companies as part of our underwriting—not only when an exit approaches.

Strategic relevance from the outset.

Building an important medical device?

We welcome conversations with founders and investors working at the leading edge of diagnosis, intervention, and patient care.
Start a conversation →